GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:22 2026-02-06 am EST			5-day change	1st Jan Change
2,198.00 ^GBX	+0.83%		+17.13%	+20.47%

Feb. 06	European Stocks Track Higher in Friday Trading; Stellantis Tanks on $26.5 Billion Write-Down	MT
Feb. 06	GSK Chair Jonathan Symonds buys GBP53,000 in shares	AN

GSK : Gets a Neutral rating from Deutsche Bank

Published on 01/16/2026 at 05:38 am EST

MarketScreener with dpa-AFX Analyser

GSK PLC

+0.83%

Analyst Emmanuel Papadakis from Deutsche Bank research gives the stock a Neutral rating. The target price has been raised to GBX 1675 from GBX 1600.

Latest news about GSK plc

Feb. 06	European Stocks Track Higher in Friday Trading; Stellantis Tanks on $26.5 Billion Write-Down	MT
Feb. 06	GSK Chair Jonathan Symonds buys GBP53,000 in shares	AN
Feb. 06	GSK plc Announces Nucala (Mepolizumab) Approval by European Commission for Treatment of Chronic Obstructive Pulmonary Disease	CI
Feb. 06	Markets Ask the Obvious Question
Feb. 06	GSK Says European Commission Approves Nucala to Treat Chronic Obstructive Pulmonary Disease	MT
Feb. 06	Oddo BHF cuts Wizz Air and Ryanair	AN
Feb. 06	FTSE 100 falls as AI fears pressure data stocks	AN
Feb. 06	EU regulator greenlights GSK lung disease therapy Nucala	AN
Feb. 06	UK house prices rise more than expected in January	AN
Feb. 06	GSK Wins EU Nod for Nucala in Uncontrolled Chronic Obstructive PulmonaryDisease	MT
Feb. 06	GSK : Receives a Sell rating from JP Morgan	ZD
Feb. 06	GSK says Nucala COPD approved by the European Commission	RE
Feb. 06	Markets are seasick
Feb. 06	AlphaValue/Baader Europe Keeps 'Favorable Stance' on GSK After Q4 2025 Beat	MT
Feb. 05	European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading	MT
Feb. 05	US tech malaise, mining deal flop weigh on FTSE	AN
Feb. 05	GSK PLC : Eventually getting into its stride
Feb. 05	Morningstar Downgrades GSK to Hold	MT
Feb. 05	GSK : JP Morgan gives a Sell rating	ZD
Feb. 05	GSK : Deutsche Bank remains Neutral	ZD
Feb. 05	Berenberg cuts Fresnillo; Citi cuts Babcock	AN
Feb. 05	UK Stocks-Factors to watch on February 5	RE
Feb. 04	As software stocks slump, investors debate AI's existential threat	RE
Feb. 04	Novo Nordisk risks weight-loss price war as discount pressures deepen	RE
Feb. 04	UK Shares Hit New Peak Ahead of Central Bank Move; Beazley Surges on Potential Merger	MT

GSK plc is a global biopharma company. The Companyâ€™s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

68,629

Sector

Pharmaceuticals

Calendar

Apr. 29 - Q1 2026 Earnings Release

More about the company